BREAKING ADVANCES

6377  Highlights from Recent Cancer Literature

REVIEWS

6379  Decoding the Histone Code: Role of H3K36me3 in Mismatch Repair and Implications for Cancer Susceptibility and Therapy
Guo-Min Li

6384  Real-time Liquid Biopsy in Cancer Patients: Fact or Fiction?
Klaus Pantel and Catherine Alexa-Panabières

MEETING REPORT

6389  The Hippo Tumor Suppressor Network: From Organ Size Control to Stem Cells and Cancer
Georg Halder and Fernando D. Camargo

PRIORITY REPORT

6393  Erythropoietin Activates Cell Survival Pathways in Breast Cancer Stem-like Cells to Protect Them from Chemotherapy
Matilde Todaro, Alice Turdo, Monica Bartucci, Flora Iovino, Rosanna Dattilo, Marco Biffoni, Giorgio Stassi, Giulia Federici, Ruggero De Maria, and Ann Zeuner

PRÉCIS: A growth factor that has been used in the oncology clinic to support red blood cell counts in patients receiving chemotherapy is found to counter the therapeutic killing of cancer stem-like cells, offering a mechanistic explanation for why cancer patients receiving this growth factor have shown reduced survival.

INTEGRATED SYSTEMS AND TECHNOLOGIES

6401  A Transcriptional and Metabolic Signature of Primary Aneuploidy Is Present in Chromosomally Unstable Cancer Cells and Informs Clinical Prognosis
Jason M. Sheltzer

PRÉCIS: Chromosomal instability in cancer cells is associated with a transcriptional stress response that has prognostic significance in various types of human malignancy.

MOLECULAR AND CELLULAR PATHOBIOLOGY

6435  miR-153 Supports Colorectal Cancer Progression via Pleiotropic Effects That Enhance Invasion and Chemotherapeutic Resistance
Lei Zhang, Karen Pickard, Veronika Jenei, Marc D. Bullock, Amanda Bruce, Richard Mitter, Gavin Kelly, Christos Paraskeva, John Strefford, John Primrose, Gareth J. Thomas, Graham Packham, and Alex H. Mirnezami

PRÉCIS: MicroRNAs that facilitate progression and mediate drug resistance in advanced cancers have increased appeal as treatment targets, given the more frequent lack of effective therapies at late stages of disease.

MICROENVIRONMENT AND IMMUNOLOGY

6413  GM-CSF Promotes the Immunosuppressive Activity of Glioma-Infiltrating Myeloid Cells through Interleukin-4 Receptor-ξ
Gary Kohanbash, Kayla McKaveney, Masashi Sakaki, Ryo Ueda, Arlan H. Mintz, Nduka Amankulu, Mitsuji Fujita, John R. Ohiest, and Hideho Okada

PRÉCIS: These findings reveal the operation of immunosuppressive mechanisms in the glioblastoma microenvironment driven by GM-CSF, a factor used in the clinic to elevate white blood cell counts in patients, suggesting clinical risks arising from its use.

6424  Substance P Autocrine Signaling Contributes to Persistent HER2 Activation That Drives Malignant Progression and Drug Resistance in Breast Cancer
Susana Garcia-Recio, Gemma Fuster, Patricia Fernandez-Nogueira, Eva M. Pastor-Arroyo, So Yeon Park, Cristina Mayordomo, Elisabet Ametller, Mario Mancino, Xavier Gonzalez-Farre, Hege G. Russnes, Pablo Engel, Domiziana Costamagna, Pedro L. Fernandez, Pedro Gascón, and Vanessa Almendro

PRÉCIS: This work illuminates the oncogenic cooperation between HER2 and a substance P receptor involved in pain signaling, providing a novel link between cancer inflammation and progression that might be targeted by substance P antagonists being explored in the clinic.
Mutually Activated PIK3CA<sup>H1047R</sup> Cooperates with BRAF<sup>V600E</sup> to Promote Lung Cancer Progression

Christy L. Trejo, Shon Green, Victoria Marsh, Eric A. Collisson, Gioia Iezza, Wayne A. Phillips, and Martin McMahon

Précis: These findings deepen the in vivo evidence that MAPK and PI3K signaling cooperates in mediating the development and progression of KRAS-mutated lung cancer, suggesting combination therapies to treat this disease.

THERAPEUTICS, TARGETS, AND CHEMICAL BIOLOGY

Photodynamic Therapy of Murine Mastocytoma Induces Specific Immune Responses against the Cancer/Testis Antigen P1A
Pawel Mroz, Fatma Vatansever, Angelika Muchowicz, and Michael R. Hamblin

Précis: Effective photodynamic therapy used to treat certain cancers may act as antigen-specific immunotherapy.

Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance through Comprehensive Blockade of ErbB2 Heterodimerization
Bohua Li, Yanchun Meng, Lei Zheng, Xumin Zhang, Qingsong Tong, Wenlong Tan, Shi Hu, Hui Li, Yang Chen, Jining Song, Ge Zhang, Lei Zhao, Dapeng Zhang, Sheng Hou, Weizhu Qian, and Yujun Guo

Précis: Using a bispecific antibody to block ErbB2/HER2 heterodimerization on the surface of breast cancer cells may provide a strategy to overcome resistance to Herceptin that remains a major clinical challenge in breast cancer patients.

A Small-Molecule Blocking Ribonucleotide Reductase Holoenzyme Formation Inhibits Cancer Cell Growth and Overcomes Drug Resistance

Précis: These findings address deficiencies in existing drugs that block ribonucleotide reductase, offering preclinical validation of a promising new class of inhibitors against this valid target that could find broad use to treat many human cancers.

Antitumor Efficacy of a Monoclonal Antibody That Inhibits the Activity of Cancer-Associated Carbonic Anhydrase XII
Gabor Gondi, Josef Mysliwietz, Alzbeta Hulikova, Jian Ping Jen, Pawel Swietach, Elisabeth Kremmer, and Reinhard Zeidler

Précis: This study offers a preclinical proof-of-concept for immune targeting a cell surface carbonic anhydrase that is widely expressed in human cancer as a general therapeutic strategy.

CORRECTION

Correction: Breast Tumor Kinase (Brk/PTK6) Is a Mediator of Hypoxia-Associated Breast Cancer Progression
miR-153 leads to increased invasiveness in colorectal cancer. Using mouse tumor xenografts, it was found that colorectal tumors with inhibition of miR-153 show a clean edge of tumor spheroid and fewer invasive fronts into the surrounding stroma (magnification, ×400) in contrast to controls with a more locally invasive tumor phenotype. For details, see article by Zhang and colleagues on page 6435.
73 (21)


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/73/21

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/73/21.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.